LUCIUS 卢修斯 贝组替凡 Belzutifan希佩尔-林道综合征 晚期肾细胞癌

贝组替凡

美国FDA批准上市产品,疗效确切
卢修斯制药(老挝)有限公司出品

Belzutifan

老挝国家食药监局批准上市
老挝国家药检所检测认证
希佩尔-林道综合征

omposition:
Each film-coated tablet contains Belzutiran

LUCiUS

PHARMACEUTICALS

Indication

晚期肾细胞癌

L uciBelzu is a hvpoxia-inducible factor
inhibitor indicated for treatment of adu
patients with von Hipel-Lindau (VHL
disease who require therapy for associated

Rx only

renal cell carcinoma (RCC), central nervau
suctem (CNSI hemanosonlastomas. or

LuciBelzu

pancrealic neuroendocrine tumors (pNEl)
not requiring immediate surgcry
Dosaao and Iise:
nended dosage of LuciBelzu 1s

Belzutifan Tablets

全球首仿

120 mg administered orally once daily with or
without Tood.
Storage: in a dry place and store at 20C1o

Warning

40mg

Keep medicine out of reach of Children. Do

andaeibelzuduring Pregnancy

PLEASE SEE PACKAGE INSERT

FDA批准

Manufactured and Marketed by:

LUCIUS

Thongmang village, Xaythany district,
vientiane Capital, Laos
www.lucius.a

权威认证

Warning: To be sold by retail on ntesornto
ol regislered phusicians orly, and as directed

by the physician

d on prescripton

90 Tablets

口碑质量

适应症:
1、希佩尔-林道综合征(VHL):贝组替凡适用于治疗相关肾细胞癌
(RCC)、中枢神经系统(CNS)血管母细胞瘤或胰腺神经内分泌肿瘤
(pNET)的成年希佩尔-林道综合征(VHL)患者,无需立即手术。
2、晚期肾细胞癌(RCC):贝组替凡适用于治疗接受程序性死亡受

体1(PD-1)或程序性死亡配体1(PD-L1)抑制剂和血管内皮生
长因子酪氨酸激酶抑制剂(VEGF-TKI)治疗后的成年晚期肾细胞
癌(RCC)患者。
推荐剂量:
每日口服一次,每次120mg,可与食物同服或单独服用。